@article{Chacón_Mendivelso_Gómez_González_Pinto_Yama_Moscoso_Acevedo_Bohórquez_Rincón_Ruiz_Espitia Malagón_Isaza_Aroca_Tovar_Luján_Rodríguez_Hamann_Yomayusa_2021, title={Comparative effectiveness and safety of Sodium-glucose Cotransporter-2 (SGLT2) inhibitors in type 2 diabetes mellitus: rapid review of systematic reviews and meta-analyzes}, volume={7}, url={https://revistaendocrino.org/index.php/rcedm/article/view/648}, DOI={10.53853/encr.7.4.648}, abstractNote={<p><strong><em>Aim:</em></strong><em> To evaluate the evidence of effectiveness and safety of sodium glucose co-transporter inhibitors type 2 (iSGLT2) in patients with type 2 diabetes mellitus. </em></p> <p><strong><em>Methodology: </em></strong><em>A rapid systematic review of systematic reviews of iSGLT2 was performed in the Medline and Embase databases until September 2019. Cardiovascular outcome was major cardiovascular adverse events (MACE): death due to cardiovascular causes, non-fatal stroke and acute non-fatal myocardial infarction, in addition to hospitalization for heart failure; renal outcome was progression of renal disease, decrease in glomerular filtration rate and albumin-creatinine ratio. The safety outcome comprehended hypoglycemia, fractures, and urinary infections. The methodological quality was evaluated with the modified A measurement Tool to Assess Systematic Review (AMSTAR-2) tool. </em></p> <p><strong><em>Results:</em></strong><em> Five systematic reviews of the literature of medium and high-quality AMSTAR-2 were included. The iSGLT2 reduces the risk of cardiovascular mortality by 23%, from all-cause mortality by 20% and in hospital admission for heart failure in 33% versus standard care. In addition, the iSGLT2 slows the deterioration of renal disease and reduces the progression to albumin in patients with documented proteinuria. In the safety outcome, there is a greater possibility of developing genitourinary tract infections with respect to oral antidiabetics. </em></p> <p><strong><em>Conclusions: </em></strong><em>The evidence suggests that iSGLT2 are effective in reducing the risk of cardiovascular mortality, all-cause mortality, hospital admission for heart failure, progression of nephropathy and the development of end-stage renal disease. In safety outcomes, the evidence suggests that iSGLT2 have a lower risk of hypoglycemic events.</em></p>}, number={4}, journal={Revista Colombiana de Endocrinología, Diabetes & Metabolismo}, author={Chacón, K. and Mendivelso, F. and Gómez, O. and González , C. and Pinto, D. and Yama, E. and Moscoso, E. and Acevedo, JR and Bohórquez, LF and Rincón, O. and Ruiz, PC and Espitia Malagón , RA and Isaza, M. and Aroca, G. and Tovar, H. and Luján, D. and Rodríguez, M. and Hamann, O. and Yomayusa, N.}, year={2021}, month={Jun.}, pages={222–234} }